Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Pembrolizumab in Recurrent and/or Metastatic Salivary Gland Malignancies
NCT04895735Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jul 2021
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and pemetrexed in salivary gland cancer (SGC), sponsored by Mayo Clinic. Primary endpoints: Confirmed Response Rate at 24 weeks and Clinical Benefit Rate at 24 weeks. Started Jul 2021; status: active, not recruiting.
02
Drugs
pembrolizumabpemetrexed
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT04895735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895735.